DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Phase 2

Recruiting

Conditions: Osteosarcoma Recurrent
Osteosarcoma

Interventions: Drug: Olaparib
Drug: Ceralasertib

First Posted Date: 2020-06-04

Last Posted Date: 2024-07-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 63

Registration Number: NCT04417062

Locations: 🇺🇸
Dana Farber Cancer Institite, Boston, Massachusetts, United States
🇺🇸
MD Anderson, Houston, Texas, United States
🇺🇸
UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology, San Francisco, California, United States

and more 1 locations

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Phase 2

Recruiting

Conditions: Chordoma (Poorly Differentiated or De-differentiated)
Other SMARCA4-deficient Malignant Tumors (With PI Approval)
Atypical Teratoid/Rhabdoid Tumor
Other INI1 Negative Tumors (With PI Approval)
Rhabdoid Tumor of the Kidney
Malignant Rhabdoid Tumor
Epithelioid Sarcoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2020-06-04

Last Posted Date: 2023-11-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT04416568

Locations: 🇺🇸
Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

and more 5 locations

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Phase 2

Terminated

Conditions: Glioblastoma
Recurrent Glioblastoma

Interventions: Drug: VB11
Procedure: Surgery
Other: Placebo
Drug: Bevacizumab

First Posted Date: 2020-05-28

Last Posted Date: 2024-08-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT04406272

Locations: 🇺🇸
Huntsman Cancer Institute (HCI), University of Utah, Salt Lake City, Utah, United States
🇺🇸
University of California, Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

YES Study - Newly Diagnosed/Metastatic Intervention

Not Applicable

Recruiting

Conditions: Breast Cancer
Symptom, Behavioral

Interventions: Behavioral: YES portal

First Posted Date: 2020-05-07

Last Posted Date: 2024-05-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 400

Registration Number: NCT04379414

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

CONFIRM: Magnetic Resonance Guided Radiation Therapy

Not Applicable

Recruiting

Conditions: Invasive Breast Cancer
Mantle Cell Lymphoma
Larynx Cancer
Bladder Cancer
Gastric Cancer
in Situ Breast Cancer

Interventions: Radiation: Viewray MRIdian® Linac

First Posted Date: 2020-04-30

Last Posted Date: 2024-08-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 70

Registration Number: NCT04368702

Locations: 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care

Not Applicable

Withdrawn

Conditions: Gynecologic Cancer
Cervical Cancer
Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma
Uterine Cancer

Interventions: Behavioral: SIGNAL

First Posted Date: 2020-04-29

Last Posted Date: 2022-10-14

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT04368130

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Step Into Support for Endurance and Strength (SISTERS)

Not Applicable

Completed

Conditions: Gynecologic Cancer

Interventions: Other: Fitbit
Other: Fitbit + Game + Support from a Teammate

First Posted Date: 2020-04-21

Last Posted Date: 2023-04-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT04354454

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Northern Light Cancer Care, Brewer, Maine, United States
🇺🇸
Lifespan Comprehensive Cancer Center, Providence, Rhode Island, United States

Phase I Study of Marizomib + Panobinostat for Children With DIPG

Phase 1

Terminated

Conditions: Diffuse Intrinsic Pontine Glioma
Pediatric Brainstem Glioma
Pediatric Brainstem Gliosarcoma, Recurrent
Pediatric Cancer
Pediatric Brain Tumor
Diffuse Glioma

Interventions: Drug: Marizomib
Drug: Panobinostat

First Posted Date: 2020-04-10

Last Posted Date: 2024-02-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 4

Registration Number: NCT04341311

Locations: 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Cemiplimab in AlloSCT/SOT Recipients With CSCC

Phase 1

Active, not recruiting

Conditions: Advanced Cancer
Cutaneous Squamous Cell Carcinoma

Interventions: Drug: Cemiplimab
Drug: Everolimus
Drug: Sirolimus
Drug: Prednisone

First Posted Date: 2020-04-08

Last Posted Date: 2024-06-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT04339062

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers

Not Applicable

Completed

Conditions: Metastatic Prostate Cancer
Ovarian Cancer
Pancreatic Cancer
Breast Cancer

Interventions: Behavioral: Standard Genetic Counseling
Behavioral: Educational Video

First Posted Date: 2020-04-01

Last Posted Date: 2024-01-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 269

Registration Number: NCT04330716

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton, Massachusetts, United States
🇺🇸
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford, Massachusetts, United States

and more 3 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy